38771-21-0 Usage
Description
4-BROMO-1-BUTYNE is an organic compound characterized by the presence of a bromine atom and a butynyl group. It is a versatile building block in organic synthesis and has a wide range of applications in various industries.
Uses
Used in Pharmaceutical Industry:
4-BROMO-1-BUTYNE is used as a pharmaceutical intermediate for the synthesis of various drugs and medicinal compounds. Its unique structure allows for the development of new and innovative pharmaceuticals.
Used in Chemical Synthesis:
4-BROMO-1-BUTYNE is used as a reactant in the synthesis of various complex organic molecules. Some of its applications include:
Macrocycles: It is used in the cobalt-mediated [2+2+2] co-cyclotrimerization process to form macrocyclic compounds.
2,4,5-trisubstituted oxazoles: It is used in a gold-catalyzed formal [3+2] cycloaddition to synthesize 2,4,5-trisubstituted oxazoles.
1,3,4-oxadiazoles: It is used in intramolecular 1,3-dipolar cycloaddition reactions to form 1,3,4-oxadiazoles.
Azulene derivatives: It is used in the reductive cyclization of lactones bearing alkynes to prepare azulene derivatives.
Substituted α-pyrones: It is used in gold-catalyzed coupling reactions to synthesize substituted α-pyrones.
Overall, 4-BROMO-1-BUTYNE is a valuable compound in the fields of pharmaceuticals and organic synthesis, offering a wide range of applications and opportunities for the development of new and innovative products.
Check Digit Verification of cas no
The CAS Registry Mumber 38771-21-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,8,7,7 and 1 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 38771-21:
(7*3)+(6*8)+(5*7)+(4*7)+(3*1)+(2*2)+(1*1)=140
140 % 10 = 0
So 38771-21-0 is a valid CAS Registry Number.
InChI:InChI=1/C4H5Br/c1-2-3-4-5/h1H,3-4H2
38771-21-0Relevant articles and documents
HYBRID NECROPTOSIS INHIBITORS
-
Page/Page column 57, (2014/09/29)
The present invention relates to heterocyclic compounds (e.g., compounds described by Formula (I)) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role. The heterocyclic compounds described herein can also achieve improved activity and selectivity towards RIP1 and/or RIP3.
Convenient and general synthesis of 1-monoorganyl- And 1,2-diorganylcyclobutenes via cyclialkylation
Negishi, Ei-Ichi,Liu, Fang,Choueiry, Daniele,Mohamud, Mohamud M.,Silveira Jr., Augustine,Reeves, Mark
, p. 8325 - 8328 (2007/10/03)
-
2-AMINOMETHYLALKYNYLALKYL-1,3-DITHIANE DERIVATIVES
-
, (2008/06/13)
-